CytomX Therapeutics, Inc. (CTMX)

NMS – Real vaqt narxi. Valyuta: USD

3.88

+0.02 (0.52%)

Yopilishda: May 12, 2026, 4:00 PM EDT

3.91

+0.03 (0.77%)

Bozor oldidan: May 13, 2026, 8:57 AM EDT

08.05.2026

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

08.05.2026

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.27 per share a year ago.

07.05.2026

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - Enrollment of 40 patients in Varseta-M Dose Optimization completed; data update expected in 2H 2026 to inform monotherapy dose selection and potential registrational trial in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab is ongoing with initial data expected by 1H 2027; Phase 1/2 Varseta-M chemotherapy combination study to be initiated in 2H 2026 - - Initiation of Phase 1 expansion cohort(s) in non-CRC indications planned for 2H 2026 - - Company to host conference call today at 5 p.m. ET / 2 p.m.

30.04.2026

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday, May 7, 2026, after the close of U.S. markets.

18.03.2026

Why Is CytomX Therapeutics Stock Falling On Wednesday?

On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.

18.03.2026

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level

CytomX Therapeutics (CTMX) has generated significant excitement with strong early data for varsetatug masetecan in refractory colorectal cancer. Phase 1 results show 20–32% response rates and median PFS of 6.8–7.1 months, outperforming current treatments in this setting. CTMX is executing a $250 million equity raise, extending its cash runway and positioning for registrational studies, but remains pre-commercial.

18.03.2026

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the public of $5.30 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,179,245 shares of common stock. The gross proceeds to CytomX from the offering are expected to be $250 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, CytomX granted the underwriters a 30-day option to purchase up to an additional 7,075,471 shares of its common stock at the public offering price, less underwriting discounts and commissions. The closing of the offering is expected to occur on March 19, 2026, subject to customary closing conditions. All of the shares of common stock and pre-funded warrants are being sold by CytomX.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

18.03.2026

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

16.03.2026

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants.

16.03.2026

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -

CytomX Therapeutics, Inc. (CTMX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Videolar

No Data

Press-relizlar

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Videolar

No Data

Press-relizlar

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

Search stocks

CytomX Therapeutics, Inc. (CTMX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Videolar

No Data

Press-relizlar

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Videolar

No Data

Press-relizlar

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update